Basal Cell Carcinoma (Basal Cell Epithelioma) Pipeline Review H1 2015 Market Research Report

DALLAS, June 3, 2015 /PRNewswire/ --

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2015 market research report provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma)'s therapeutic pipeline for H1 2015.

The complete Basal Cell Carcinoma market (Basal Cell Epithelioma) pipeline report spread across 81 pages, talking about 11 companies and supported with 29 tables and 15 figures is now available at http://www.reportsnreports.com/reports/401448-basal-cell-carcinoma-basal-cell-epithelioma-pipeline-review-h1-2015.html .

This report provides comprehensive information on the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and special features on late-stage and discontinued projects. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

The Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2015 research provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies while identifying emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. The report helps develop strategic initiatives by understanding the focus areas of leading companies as well as identify and understand important and diverse types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma). The information of this study helps to plan mergers and acquisitions effectively by identifying key players of the most promising pipeline and devise corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline depth and focus of Indication therapeutics. This new H1 2015 report on Basal Cell Carcinoma (Basal Cell Epithelioma) also helps in developing and designing in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope while providing required help to modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies mentioned in this H1 2015 basal cell carcinoma / basal cell Epithelioma pipeline review report include 4SC AG, Biofrontera AG, Biogenomics Limited, Biosceptre International Limited, Bristol-Myers Squibb Company, Genextra S.p.a., MediGene AG, Novartis AG, Oncovir, Inc., Redx Pharma Ltd and Transgene SA. Drug profiles mentioned in this research include aminolevulinic acid hydrochloride, BIL-010t, BMS-833923, CIGB-128, CS-S/BCC-1, CS-TATI-1, DAC-060, erismodegib, interferon alfa-2b (recombinant), LEQ-506, Oshadi D + Oshadi R, Poly-ICLC, sinecatechins, Small Molecule to Inhibit Smoothened Receptor for Basal Cell Carcinoma , Small Molecules to Inhibit Casein Kinase 1 for Cancer and TG-1042. Order a copy of this research at http://www.reportsnreports.com/Purchase.aspx?name=401448 .

The report provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Basal Cell Epithelioma). The research reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. It also reviews key players involved in the therapeutics development for Basal Cell Carcinoma (Basal Cell Epithelioma) and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects. A review of the Basal Cell Carcinoma (Basal Cell Epithelioma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources is provided along with pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. A detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline on the basis of target, MoA, route of administration and molecule type as well as latest news and deals relating related to pipeline products are also covered in this research.

Global Markets Direct reports features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

On similar lines, ReportsnReports.com also offers Nonmelanomatous Skin Cancer - Pipeline Review, H1 2015 research report that talks about companies like Advancell, EcoBiotics Limited, LEO Pharma A/S and Spherium Biomed S.L. along with drug profiles like ANs-40, ANS-401, ANS-403, EBC-46, OXT-328, Recombinant Peptide for Dermatology, Immunology and Oncology, Small Molecules to Activate Protein Kinase C for Dermatology and Cancer, Small Molecules to Inhibit PLK1 for Cutaneous Squamous Cell Carcinoma and Vaccine for HPV Associated Skin Cancer.

Explore more reports on the pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  

Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689

LinkedIn: www.linkedin.com/company/reportsnreports

Twitter: https://twitter.com/marketsreports

G+ / Google Plus:  https://plus.google.com/111656568937629536321/posts

Pinterest: www.pinterest.com/comeonseo/reportsnreports/

RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@reportsandreports.com